Investors burned by President Trump’s trade fight now have to contend with a spending megabill that risks swelling the ...

The new owner, Regeneron Pharmaceuticals intends to continue providing 23andMe’s consumer genome services, it said.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.

South San Francisco, California-based 23andMe filed for bankruptcy last month, seeking to sell its business at auction after ...

Wall Street indices closed mixed on Monday. Moody's downgraded the U.S. credit rating due to rising debt. S&P 500 marked its ...

Scott Adams, the creator of the "Dilbert" comic strip, revealed Monday he is battling the same metastatic prostate cancer as ...

Regeneron Pharmaceuticals is acquiring the assets of 23andMe for $256 million, excluding its Lemonaid Health business, as the ...

Regeneron Pharmaceuticals said it would acquire 23andMe, which filed for bankruptcy in March and would continue to offer ...

Pharmaceutical giant Regeneron has emerged as the winning bidder for consumer genetics company 23andMe in a court-supervised ...

CBS News President Wendy McMahon announced Monday her resignation as network head amid an ongoing lawsuit with the network ...

The U.S. FDA cleared Novavax Inc.’s COVID-19 vaccine Nuvaxovid for adults 65 and over and people 12-64 years old with at least one underlying condition that puts them at risk of severe outcomes from ...

Regeneron Pharmaceuticals has bought the genetic testing company 23andMe, a company once valued at $6bn, for $256m through a ...